Chinese medical device firm BRONCUS-B (02216) has unveiled its financial performance for the six-month period ended June 30, 2026, revealing a notable surge in revenue alongside a widening adjusted loss.

The company recorded revenue of $3.29 million for the interim period, marking a substantial 99% year-on-year increase. Meanwhile, the adjusted net loss stood at $7.98 million, reflecting a 14.7% expansion compared to the prior corresponding period. The loss per share was reported at $0.02.

According to the official announcement, the revenue growth was primarily driven by the Chinese market, where both equipment and consumables segments delivered year-on-year increases during the reporting period.